NASDAQ: INSMInsmed Inc Stock
$98.73+1.85 (+1.91%)
Updated Jun 13, 2025
INSM Price
$98.73
Fair Value Price
-$83.18
Market Cap
$17.98B
52 Week Low
$60.40
52 Week High
$100.00
P/E
-16.65x
P/B
181.35x
P/S
36.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$381.03M
Earnings
-$1.01B
Gross Margin
76.5%
Operating Margin
-242.45%
Profit Margin
-265.9%
Debt to Equity
17.18
Operating Cash Flow
-$762M
Beta
1.07
Next Earnings
Jul 31, 2025
Ex-Dividend
N/A
Next Dividend
N/A
INSM Overview
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INSM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INSM
Ranked#181 of 464
Ranked#181 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important INSM news, forecast changes, insider trades & much more!
INSM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INSM ($98.73) is overvalued by 218.69% relative to our estimate of its Fair Value price of -$83.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INSM ($98.73) is not significantly undervalued (218.69%) relative to our estimate of its Fair Value price of -$83.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INSM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INSM due diligence checks available for Premium users.
Valuation
INSM fair value
Fair Value of INSM stock based on Discounted Cash Flow (DCF)
Price
$98.73
Fair Value
-$83.18
Undervalued by
218.69%
INSM ($98.73) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INSM ($98.73) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INSM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INSM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.65x
Industry
-108.97x
Market
31.36x
INSM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
181.35x
Industry
4.66x
INSM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INSM's financial health
Profit margin
Revenue
$92.8M
Net Income
-$256.6M
Profit Margin
-276.4%
INSM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INSM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.8B
Liabilities
$1.7B
Debt to equity
17.18
INSM's short-term assets ($1.40B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INSM's long-term liabilities ($1.46B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INSM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$262.1M
Investing
$80.4M
Financing
$29.0M
INSM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INSM vs Biotech Stocks
Insmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.